Targeting DNA damage repair precision medicine strategies in cancer

Brownlie, Juliette; Kulkarni, Sanat; Algethami, Mashael; Jeyapalan, Jennie N.; Mongan, Nigel P.; Rakha, Emad A.; Madhusudan, Srinivasan

Abstract

DNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with BRCA germline deficient breast and ovarian cancer as well as platinum sensitive epithelial ovarian cancers. However, lessons learnt from the clinical use of PARP inhibitors also confirm that not all patients respond either due to intrinsic or acquired resistance. Therefore, the search for additional synthetic lethality approaches is an active area of translational and clinical research. Here, we review the current clinical state of PARP inhibitors and other evolving DNA repair targets including ATM, ATR, WEE1 inhibitors and others in cancer.

Citation

Brownlie, J., Kulkarni, S., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2023). Targeting DNA damage repair precision medicine strategies in cancer. Current Opinion in Pharmacology, 70, Article 102381. https://doi.org/10.1016/j.coph.2023.102381

• Journal Article Type: Article
• Acceptance Date: May 1, 2023
• Online Publication Date: May 4, 2023
• Publication Date: 2023-06
• Deposit Date: Nov 4, 2023
• Publicly Available Date: Nov 6, 2023
• Journal: Current Opinion in Pharmacology
• Print ISSN: 1471-4892
• Electronic ISSN: 1471-4973
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 70
• Article Number: 102381
• DOI: https://doi.org/10.1016/j.coph.2023.102381
• Keywords: Drug Discovery; Pharmacology
• Public URL: https://nottingham-repository.worktribe.com/output/20287943
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S1471489223000346?via%3Dihub